Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.73 USD | -3.37% | -5.81% | +6.27% |
Jun. 13 | Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease | CI |
May. 08 | Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study | MT |
Financials (USD)
Sales 2024 * | 24.88M | Sales 2025 * | 32.7M | Capitalization | 229M |
---|---|---|---|---|---|
Net income 2024 * | -10M | Net income 2025 * | -29M | EV / Sales 2024 * | 9.22 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.01 x |
P/E ratio 2024 * |
-19.3
x | P/E ratio 2025 * |
-7.64
x | Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.9% |
Latest transcript on Aldeyra Therapeutics, Inc.
1 day | -3.37% | ||
1 week | -5.81% | ||
Current month | -3.37% | ||
1 month | +0.81% | ||
3 months | +28.62% | ||
6 months | +21.10% | ||
Current year | +6.27% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Brady
CEO | Chief Executive Officer | 52 | 05-08-31 |
Bruce Greenberg
DFI | Director of Finance/CFO | 56 | 19-11-30 |
Caitlin Pazzano
PRN | Corporate Officer/Principal | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 58 | 09-04-30 |
Martin Joyce
BRD | Director/Board Member | 70 | 13-09-30 |
Ben Bronstein
BRD | Director/Board Member | 74 | 10-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 32 M€ | +3.87% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-14 | 3.73 | -3.37% | 396,947 |
24-06-13 | 3.86 | -0.77% | 162,056 |
24-06-12 | 3.89 | +3.18% | 377,735 |
24-06-11 | 3.77 | -2.58% | 342,937 |
24-06-10 | 3.87 | +0.26% | 197,263 |
Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.27% | 229M | |
+18.15% | 124B | |
+18.02% | 111B | |
-12.75% | 23.17B | |
+5.07% | 22.94B | |
-39.94% | 17.42B | |
-9.86% | 17.42B | |
-14.97% | 16.9B | |
+2.80% | 13.71B | |
+27.39% | 11.82B |
- Stock Market
- Equities
- ALDX Stock